Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$26.21M |
$0.60
+2.54%
|
|
CUE
Cue Biopharma, Inc.
CUE Biopharma is developing oncology-focused immunotherapies and cancer programs, aligning with Biotech - Oncology.
|
$25.93M |
$0.33
+9.43%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$24.85M |
$22.55
+0.11%
|
|
PLUR
Pluri Inc.
PluriCDMO provides cell-therapy manufacturing services, generating revenue and serving as a core business line.
|
$24.55M |
$3.02
+0.33%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$23.52M |
$0.37
-7.11%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$22.37M |
$1.08
-0.92%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$21.68M |
$0.61
-2.88%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$21.59M |
$0.67
-4.33%
|
|
LIMN
Liminatus Pharma, Inc. Class A Common Stock
Directly aligned with LIMN's focus on cancer therapies (anti-CD47 antibody) within the biotech-oncology space.
|
$21.33M |
$0.80
-2.45%
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$20.62M |
$1.75
+6.71%
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$20.43M |
$0.42
-2.97%
|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$20.35M |
$0.28
-31.68%
|
|
KAPA
Kairos Pharma, Ltd.
Kairos Pharma is a clinical-stage biopharma focused on oncology therapies, including immunotherapies and cell therapies.
|
$20.12M |
$0.94
-3.49%
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$19.99M |
$0.92
+9.98%
|
|
CVM
CEL-SCI Corporation
Direct product category for CEL-SCI's lead immunotherapy for cancer (Multikine) under oncology biotech.
|
$19.30M |
$6.07
-4.64%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN310 is a monoclonal antibody therapeutic targeting toxic amyloid-beta oligomers for Alzheimer's disease.
|
$18.63M |
$8.62
-1.54%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$18.04M |
$2.04
-0.73%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$17.40M |
$1.18
-0.84%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$17.33M |
$1.96
+2.89%
|
|
SXTC
China SXT Pharmaceuticals, Inc.
SXTC manufactures TCMP products and operates GMP-compliant production lines, consistent with a contract manufacturing organization (CMO) model.
|
$17.20M |
$0.74
-40.40%
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$17.15M |
$0.30
-0.03%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$17.11M |
$3.69
-1.73%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$16.51M |
$1.07
+0.47%
|
|
CLGN
CollPlant Biotechnologies Ltd.
rhCollagen is a recombinant protein, and CollPlant's core product is plant-derived recombinant human collagen used in implants, fillers, and bioinks.
|
$16.49M |
$1.46
+1.39%
|
|
MDXH
MDxHealth S.A.
GPS test provides biomarker-based risk stratification that informs treatment decisions, aligning with Companion Diagnostics.
|
$16.19M |
$3.26
-0.31%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$16.13M |
$8.08
+2.54%
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$15.67M |
$0.56
+7.69%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$15.34M |
$0.34
-0.29%
|
|
CTXR
Citius Pharmaceuticals, Inc.
LYMPHIR is a targeted oncology immunotherapy for CTCL, representing a core commercial product.
|
$15.31M |
$0.86
-4.00%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$15.12M |
$1.31
|
|
ADAP
Adaptimmune Therapeutics plc
Adaptimmune develops engineered T-cell therapies (cell therapy) for cancer, including TECELRA and lete-cel.
|
$14.58M |
$0.06
+2.91%
|
|
VYNE
VYNE Therapeutics Inc.
Company's core focus is immunology therapeutics powered by a BET inhibitor platform.
|
$14.50M |
$0.58
+1.12%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$14.45M |
$1.09
|
|
APLT
Applied Therapeutics, Inc.
Applied Therapeutics is a biotech focused on rare diseases, with lead programs in rare metabolic/neurologic conditions (e.g., govorestat for CMT-SORD) and out-licensing efforts in rare disease assets.
|
$14.43M |
$0.10
+1.20%
|
Showing page 21 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
